Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study

BACKGROUND: An upgraded understanding of factors (sex/estrogen) associated with survival benefit in advanced colorectal carcinoma (CRC) could improve personalised management and provide innovative insights into anti-tumour mechanisms. The aim of this study was to assess the efficacy and safety of ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Chunlong, Gu, Xiaoyuan, Zeng, Xianshang, Chen, Baomin, Yu, Weiguang, Chen, Meiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789412/
https://www.ncbi.nlm.nih.gov/pubmed/33413175
http://dx.doi.org/10.1186/s12885-020-07770-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789412/
https://www.ncbi.nlm.nih.gov/pubmed/33413175
http://dx.doi.org/10.1186/s12885-020-07770-9

Ejemplares similares